Newsroom

Sistema Integrato DomiciliarE e Riabilitazione Assistita al Benessere - SIDERA^B Iniziativa realizzata nell’ambito dell’Asse  I "Rafforzare la ricerca, lo sviluppo tecnologico e  l’innovazione" / Obiettivo 1b.1 "Incremento dell’attività di innovazione delle imprese" /...

Brussels/Milan, BE/IT, 6 May 2019 – The international community is preparing to celebrate World Asthma Day, tomorrow. Asthma is a disease which affects over 300 million people worldwide, a number that is set to rise to 400 million by 2025. Each year, millions of...

London/Lisbon, UK/PT, 03 July 2018 – Amiko Digital Health Limited (Amiko), a company that develops advanced medication sensor technologies and digital therapeutic solutions

POR FESR 2014-2020 – Azione I.1.b.1.2 – BANDO TECH FAST LOMBARDIA Obiettivo «Investimenti in favore della crescita e dell’occupazione» Azione I.1.b.1.2 - Sostegno alla valorizzazione economica dell’innovazione  attraverso la sperimentazione e l’adozione di soluzioni...

London/Berlin, UK/DE, 1 October 2018 – Amiko announces that its flagship Respiro platform has won the open call for innovation of the German National Association of Statutory Health Insurance Physicians (KBV). Respiro, a digital medicine offering that uses advanced...

Sanner and Amiko partner to develop digital solutions for true medication adherence Bensheim/Germany, London/UK, 13 February 2018 – How can artificial intelligence, drug

Milan, IT, 3 November 2020 – Amiko Digital Health, a leading digital medicine company, and Berry Global, a Fortune 500 global manufacturer and marketer of plastic packaging products, have announced a collaboration to launch the RS01X, a digitally-connected single-dose...

London/Berlin, UK/DE, 25 September 2018 – The Heath-I initiative by Handelsblatt and Germany’s largest public health insurance, the Techniker-Krankenkasse nominated Amiko Digital Health for this year’s Health-I Award among the top three companies that have the...

Amiko receives CE mark for use of the Respiro Platform with Teva’s Spiromax® Inhaler, Chiesi’s Nexthaler® inhaler and GlaxoSmithKline’s Ellipta® inhaler London,